Taiwan Stock Exchange · Healthcare
ScinoPharm Taiwan stock from India: price, numbers and tax
ScinoPharm Taiwan (1789) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
ScinoPharm Taiwan at a glance
- Price
- NT$18.80-NT$0.15 (0.79%)
- Market cap
- NT$14.87B
- Day range
- NT$18.70 – NT$18.95
- P/E
- 394.96
- Dividend yield
- 1.54%
- Volume
- 275.76K
- 1 month
- -1.05%
- 6 months
- -13.36%
- YTD
- +12.24%
- 1 year
- -4.57%
- 5 years
- -22.15%
ScinoPharm Taiwan statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$3.2B | NT$3.4B | NT$3.2B | NT$3.3B | NT$2.8B |
| Gross profit | NT$1.1B | NT$1.3B | NT$1.2B | NT$1.3B | NT$1.3B |
| Operating income | NT$108.9M | NT$322.7M | NT$314.5M | NT$405.6M | NT$288.7M |
| Net income | NT$137.0M | NT$339.4M | NT$287.1M | NT$353.2M | NT$243.5M |
| Earnings per share | NT$0.17 | NT$0.43 | NT$0.36 | NT$0.45 | NT$0.31 |
| EBITDA | NT$674.0M | NT$909.4M | NT$819.2M | NT$885.3M | NT$690.4M |
| Total assets | NT$11.9B | NT$11.9B | NT$11.7B | NT$11.9B | NT$11.7B |
| Total debt | NT$762.7M | NT$676.8M | NT$621.1M | NT$677.9M | NT$557.6M |
| Cash and short-term investments | NT$3.1B | NT$4.2B | NT$3.9B | NT$4.3B | NT$4.1B |
| Shareholders' equity | NT$10.5B | NT$10.5B | NT$10.4B | NT$10.5B | NT$10.5B |
| Operating cash flow | NT$597.1M | NT$750.9M | NT$231.1M | NT$773.8M | NT$509.8M |
| Free cash flow | NT$305.8M | NT$462.2M | −NT$53.6M | NT$523.7M | NT$188.5M |
| Capital expenditure | −NT$291.3M | −NT$288.7M | −NT$284.7M | −NT$250.0M | −NT$321.3M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Ever Supreme Bio Technology | 6712.TWO | $162.00 | $16.48B |
| Synmosa Biopharma | 4114.TWO | $29.50 | $15.92B |
| YungShin Global | 3705.TW | NT$56.70 | NT$15.10B |
| Visco Vision | 6782.TW | NT$237.50 | NT$14.96B |
| Excelsior Medical | 4104.TW | NT$72.70 | NT$13.69B |
| Grape King Bio | 1707.TW | NT$85.50 | NT$12.67B |
| Foresee Pharmaceuticals | 6576.TWO | $79.10 | $12.46B |
| Standard Chem & Pharm | 1720.TW | NT$56.10 | NT$11.03B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in ScinoPharm Taiwan from India
What ScinoPharm Taiwan does
ScinoPharm Taiwan, Ltd., along with its subsidiaries, specializes in the research, development, production, and global distribution of cGMP-compliant active pharmaceutical ingredients (APIs). The company supplies these APIs to pharmaceutical clients throughout Taiwan, the United States, Europe, India, various parts of Asia, and other international regions. ScinoPharm Taiwan operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell ScinoPharm Taiwan shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.